Attached files

file filename
EX-99.1 - EXHIBIT 99.1 - CASI Pharmaceuticals, Inc.v452904_ex99-1.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 14, 2016

 

CASI PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

 

DELAWARE   0-20713   58-1959440
(State or other jurisdiction of
incorporation or organization)
  (Commission File Number)   (IRS Employer
Identification No.)

 

9620 Medical Center Drive, Suite 300

Rockville, Maryland

 

(Address of principal executive offices)

 

20850

 

(Zip Code)

 

(240) 864-2600

 

(Registrant’s telephone number, including area code)

 

Not Applicable

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

   

 

 

Item 2.02   Results of Operations and Financial Condition.

 

On November 14, 2016, CASI Pharmaceuticals, Inc. (the “Company”) issued a press release reporting its financial results for the three and nine month periods ended September 30, 2016. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

 

The information on this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

 

Item 9.01   Financial Statements and Exhibits.

 

(d)Exhibits

 

99.1Press Release of CASI Pharmaceuticals, Inc., dated November 14, 2016

 

   

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CASI PHARMACEUTICALS, INC.
     
     
  /s/ Sara B. Capitelli  
  Sara B. Capitelli
  Vice President, Finance and Principal Accounting Officer

 

Date: November 14, 2016

 

   

 

 

EXHIBIT INDEX

 

Exhibit NumberDescription of Document

 

99.1Press Release of CASI Pharmaceuticals, Inc., dated November 14, 2016